2. Search Result
Search Result
Results for "

CD8<sup> </sup> T

" in MedChemExpress (MCE) Product Catalog:

3828

Inhibitors & Agonists

2

Screening Libraries

48

Fluorescent Dye

195

Biochemical Assay Reagents

294

Peptides

16

MCE Kits

201

Inhibitory Antibodies

289

Natural
Products

546

Recombinant Proteins

1108

Isotope-Labeled Compounds

126

Antibodies

53

Click Chemistry

149

Oligonucleotides

Cat. No. Product Name Target Research Area
  • HY-P990262
    Anti-Mouse CD8 Antibody (HB-129)

    		Inhibitory Antibodies Others
    Anti-Mouse CD8 Antibody (HB-129) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD8.
  • HY-P99128
    Anti-Mouse CD8 beta Antibody (53-5.8)

    		Inhibitory Antibodies Inflammation/Immunology
    Anti-Mouse CD8 beta Antibody is an anti-mouse CD8 beta IgG1 antibody inhibitor derived from host Rat.
  • HY-P991318
    AR20.5

    		Mucin Cancer
    AR20.5 is a human monoclonal antibody (mAb) targeting MUC1. AR20.5 increases the number of activated CD8 T cells, CD3+CD4−CD8−(DN) T cells, and mature dendritic cells in pancreatic tumor-bearing mice. AR20.5 can be used in anti-pancreatic cancer immunity research .
  • HY-P991402
    BI-1910

    		TNF Receptor Cancer
    BI-1910 is a human monoclonal antibody (mAb) targeting TNFRSF1B. BI-1910 enhances T cell activation and induces CD8 T cell-dependent anti-tumor effects. BI-1910 can be used in solid tumors research. Recommended isotype control: Human IgG1 lambda, Isotype Control (HY-P99992) .
  • HY-P991217
    EU-103

    		Transmembrane Glycoprotein Cancer
    EU-103 is a humanized monoclonal antibody targeting V-Set And Immunoglobulin Domain Containing 4 (VSIG4) with a KD value ranging from 10 −7 and 10 −9. EU-103 blocks the interaction between VSIG4 and CD8+ T cells, promotes the conversion of M2 macrophages into M1 macrophages, induces the proliferation of CD8+ T cells and the secretion of pro-inflammatory cytokines, thereby inhibiting tumor growth. EU-103 is promising for research of cancers, such as bladder cancer, breast cancer, and colon cancer .
  • HY-P991192
    BI-1808

    		TNF Receptor Cancer
    BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8 + T cells .
  • HY-P991191
    REGN-5054

    		Transmembrane Glycoprotein Cancer
    REGN5054 is a fully human monoclonal IgG1 antibody that binds specifically to human and cynomolgus CD8 expressed on T cells .
  • HY-P991403
    BC011

    		TNF Receptor Cancer
    BC011 is a human monoclonal antibody (mAb) targeting TNFRSF1B. BC011 promotes CD8+T cell proliferation and depletes Treg cells, thereby increasing the proportion of effector T cells in the tumor microenvironment. BC011 can be used in tumor Immunity research.
  • HY-P991456
    LMB-100

    		Mesothelin Cancer
    LMB-100 is a human immunotoxin targeting MSLN/Mesothelin. LMB-100 induces systemic inflammation and CD8 T cell recruitment. LMB-100 enhances the antitumor effects of anti-PD-1 antibodies in a human peripheral blood mononuclear cell transplanted mesothelioma mouse model and a syngeneic lung adenocarcinoma mouse model expressing human mesothelin. LMB-100 can be used in mesothelioma research. Recommended isotype control: Fab fused with a fragment of Pseudomonas exotoxin A .
  • HY-P991335
    BAT6026

    		Orexin Receptor (OX Receptor) Cancer
    BAT6026 is a human monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134. BAT6026 significantly reduces Treg cells and increased CD8+ T cells in tumor .
  • HY-P99908
    Efineptakin alfa

    NT-17

    		 Interleukin Related Cancer
    Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4 + and CD8 + cells in both human and mice. Efineptakin alfa can be used for glioblastoma research .
  • HY-P991214
    Tucotuzumab celmoleukin

    EMD 273,066; huKS-IL2

    		 Interleukin Related Cancer
    Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine fusion agent targeting the epithelial cell adhesion molecule (EpCAM). Tucotuzumab celmoleukin binds to EpCAM and delivers IL-2 to the tumor microenvironment, which can activate cytotoxic effector cells, such as CD8+ T cells and natural killer (NK) cells. Tucotuzumab celmoleukin is promising for research of EpCAM-positive cancers, such as colorectal cancer and prostate cancer .
  • HY-P99834
    Crefmirlimab

    		Transmembrane Glycoprotein Cancer
    Crefmirlimab is a humanized CD8 specific minibody. The minibody (Mb) maintains the specificity of full-length antibodies but has no immune effector functions and is biologically inert .
  • HY-P9997
    Rosnilimab

    ANB030

    		 PD-1/PD-L1 Inflammation/Immunology
    Rosnilimab (ANB030) is a PD-1 agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high PD-1 expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis .
  • HY-P991432
    VTX-0811

    		TNF Receptor NF-κB c-Myc Cancer
    VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .
  • HY-P99159
    Ivuxolimab

    		Interleukin Related Cancer
    Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4 + and CD8 + T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc .
  • HY-P99759
    Nogapendekin alfa (his tag)

    IL-15N72D

    		 Interleukin Related Inflammation/Immunology Cancer
    Nogapendekin alfa (his tag), a soluble protein subunit of a human interleukin (IL)-15 variant, is a superagonist of IL-15. Nogapendekin alfa (his tag) promotes the proliferation and viability of immune cells. Nogapendekin alfa (his tag) combines with Inbakicept (HY-P99661) at a ratio of 2:1, to form N-803 (Nogapendekin alfa inbakicept), an IL-15 cytokine antibody fusion protein. N-803 reduces tumor burden by activation of NK cells and CD8 + T cells .
  • HY-P99431
    KY-1044

    Alomfilimab; SAR 445256

    		 CD28 Inflammation/Immunology Cancer
    KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 + TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .
  • HY-P99483
    Blontuvetmab

    AT 004; VT 007

    		 CD20 Adenosine Receptor Cancer
    Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma .
  • HY-P99129
    Anti-Mouse CD8a Antibody (53-6.7)
    1 Publications Verification

    		 Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse CD8a Antibody is a anti-mouse CD8a IgG2a antibody inhibitor derived from host Rat.
  • HY-P990855
    Anti-CD8α Antibody (OKT-8)

    		Integrin Others
    Anti-CD8α Antibody (OKT-8) is a kind of mouse IgG2a chimeric antibody, targeting to human CD8α. The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978).
  • HY-P990126
    Anti-Rat CD8α Antibody (OX-8)

    		Integrin Others
    Anti-Rat CD8α Antibody (OX-8) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to rat CD8α.
  • HY-P990790
    Anti-Mouse CD8α Antibody (2.43)

    		Inhibitory Antibodies Others
    Anti-Mouse CD8α Antibody (2.43) is a kind of rat IgG2b kappa in vivo mouse antibody, targeting to CD8α. The recommend isotype control of Anti-Mouse CD8α Antibody (2.43): Rat IgG2b kappa, Isotype Control (HY-P990682).
  • HY-P991112
    Anti-Mouse CD8α Antibody (YTS169.4)

    		Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse CD8α Antibody (YTS169.4) is an IgG2 monoclonal antibody that targets CD8α. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682).
  • HY-P99790
    Priliximab

    CEN 000029; cM-T412

    		 Transmembrane Glycoprotein Inflammation/Immunology
    Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4 + T cells. Priliximab can be used in research of rheumatoid arthritis (RA) .
  • HY-P990162
    Anti-Mouse T15 VH and T15 VL regions of IgM Antibody (HB33)

    		Inhibitory Antibodies Others
    Anti-Mouse T15 VH and T15 VL regions of IgM Antibody (HB33) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse T15 VH and T15 VL regions of IgM.
  • HY-P991410
    5T4_0108

    MEDI0641 antibody

    		 Wnt Cancer
    5T4_0108 (MEDI0641 antibody) is a human monoclonal antibody (mAb) targeting TPBG. 5T4_0108 can be used in breast and prostate cancer research .
  • HY-P99837
    Dafsolimab

    SPV-T3a

    		 CD3 Infection
    Dafsolimab (SPV-T3a) is an IgG2a murine monoclonal antibody (anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/T cell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD) .
  • HY-P9947
    Efalizumab

    		Integrin Others
    Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research .
  • HY-P991307
    BND-35

    		Transmembrane Glycoprotein Cancer
    BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model .
  • HY-P990956
    Etakafusp alfa

    		Inhibitory Antibodies Inflammation/Immunology
    HY-P990956 is an CD8A/CD8B-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
  • HY-P99392
    Teclistamab

    JNJ-7957; JNJ-64007957; Tecvayli

    		 CD3 Cancer
    Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .
  • HY-P99523
    Vepsitamab

    AMG 199

    		 CD3 Cancer
    Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation .
  • HY-P99617
    Fianlimab

    REGN3767

    		 LAG-3 Inflammation/Immunology Cancer
    Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity .
  • HY-P99958
    Vixtimotamab

    AMV-564; TandAb T564

    		 Transmembrane Glycoprotein Cancer
    Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .
  • HY-P99390
    Tepoditamab

    MCLA 117

    		 CD3 Cancer
    Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research .
  • HY-P991232
    AMX-818

    		EGFR Cancer
    AMX-818 is a conditionally active, masked T cell engager (TCE) targeting HER2. AMX-818 demonstrates potent T cell cytotoxicity against HER2-positive tumor cell lines. AMX-818 can also induce tumor regression in vivo. AMX-818 is promising for research of HER2-positive solid tumors .
  • HY-P991329
    ASP-1948

    		Complement System Cancer
    ASP-1948 is a human monoclonal antibody (mAb) targeting NRP1/VEGF165R/CD34. ASP-1948 reverses the suppressive effects of regulatory T cells. ASP-1948 can be used in solid tumors research .
  • HY-P991178
    BMS-986156

    		TNF Receptor Cancer
    BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates T regulatory cells. BMS-986156 is indicated for use in advanced solid tumor studies .
  • HY-P991421
    W0180

    		VISTA Cancer
    W0180 is a human IgG1 monoclonal antibody (mAb) targeting VISTA/B7-H5. W0180 has the potential to activate T cells. W0180 can be used in solid tumors research .
  • HY-P991479
    GS-8588

    		HIV Cancer
    GS-8588 is a human bispecific antibody (bsAb) targeting gp120/Glycoprotein 120. GS-8588 induces T cell activation and cytokine secretion in PWH. GS-8588 can be used in AIDS research .
  • HY-P99382
    Vopratelimab

    JTX 2011; 37A10

    		 Inhibitory Antibodies Inflammation/Immunology Cancer
    Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response .
  • HY-P99570
    Telazorlimab

    GBR-830

    		 Inhibitory Antibodies Inflammation/Immunology
    Telazorlimab (GBR-830) is a humanized monoclonal antibody against OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for the research of autoimmune diseases .
  • HY-P991381
    JST-TfR09

    PPMX-T003

    		 Transferrin Receptor Reactive Oxygen Species (ROS) Ferroptosis Cancer
    TXB4 (PPMX-T003) is a human monoclonal antibody (mAb) targeting CD71. JST-TfR09 can induce ferroptosis by reducing ferritin levels in ATLL cell lines, increasing the generation of ferrous iron and reactive oxygen species (ROS), and inducing lipid peroxidation via malondialdehyde. JST-TfR09 can be used in leukemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
  • HY-P99607
    Clenoliximab

    IDEC-151

    		 HIV Inflammation/Immunology
    Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonal antibody (immunoglobulin G4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis .
  • HY-P99259
    Cabiralizumab

    FPA 008; Anti-Human CSF1R Recombinant Antibody

    		 c-Fms Inflammation/Immunology Cancer
    Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .
  • HY-P99152
    Muromonab

    Muromanab-CD3

    		 CD3 Interleukin Related IFNAR Inflammation/Immunology Cancer
    Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients .
  • HY-P991382
    SAR-439459

    		TGF-β Receptor Cancer
    SAR-439459 is a human monoclonal antibody (mAb) targeting TGFB1/TGFβ-1. SAR-439459 blocks TGFβ-mediated pSMAD signaling, and suppression of T cells and NK cells. SAR-439459 has anti-tumor activity .
  • HY-P99814
    Pavurutamab

    AMG-701

    		 CD3 Inflammation/Immunology Cancer
    Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
  • HY-P99430
    Alnuctamab

    EM901; CC-93269

    		 CD3 Inflammation/Immunology Cancer
    Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: